Last reviewed · How we verify
Calcipotriene + Betamethasone Dipropionate
Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone dipropionate is a potent corticosteroid that reduces inflammation and immune response in the skin.
Calcipotriene is a vitamin D analog that regulates skin cell differentiation and proliferation, while betamethasone dipropionate is a potent corticosteroid that reduces inflammation and immune response in the skin. Used for Psoriasis (plaque psoriasis and other forms), Atopic dermatitis.
At a glance
| Generic name | Calcipotriene + Betamethasone Dipropionate |
|---|---|
| Also known as | Enstilar |
| Sponsor | Odense University Hospital |
| Drug class | Vitamin D analog + Corticosteroid combination |
| Target | Vitamin D receptor (VDR) and Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene binds to vitamin D receptors on keratinocytes and immune cells, promoting normal differentiation and reducing hyperproliferation characteristic of psoriasis. Betamethasone dipropionate acts as a glucocorticoid receptor agonist, suppressing inflammatory cytokines and immune cell infiltration. The combination provides synergistic anti-inflammatory and anti-proliferative effects on psoriatic plaques.
Approved indications
- Psoriasis (plaque psoriasis and other forms)
- Atopic dermatitis
Common side effects
- Skin irritation or burning at application site
- Hypercalcemia (with prolonged use or large surface area application)
- Skin atrophy (from corticosteroid component)
- Folliculitis
Key clinical trials
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
- Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream
- Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |